Abstract. Yuan-zhi-san (YZS) is a classic type of Traditional Chinese Medicine, which has been reported to aid in the treatment of Alzheimer's disease (AD). The present study aimed to investigate the effects of YZS on tau protein aggregation, a hallmark of AD pathology, and its possible mechanisms. The results demonstrated that YZS improved learning and memory abilities, and decreased the severity of AD pathology in β-amyloid (Aβ1-40)-induced AD rats. Moreover, YZS administration inhibited the hyperphosphorylation of tau protein at Ser199 and Thr231 sites. Several vital enzymes in the ubiquitin-proteasome system (UPS), including ubiquitin-activating enzyme E1a/b, ubiquitin-conjugating enzyme E2a, carboxyl terminus of Hsc70-interacting protein, ubiquitin C-236 terminal hydrolase L1 and 26S proteasome, were all significantly downregulated in AD rats, which indicated an impaired enzymatic cascade in the UPS. In addition, it was identified that YZS treatment partly increased the expression levels of these enzymes in the brains of AD rats. In conclusion, the present results suggested that YZS could effectively suppress the hyperphosphorylation of tau proteins, which may be partially associated with its beneficial role in restoring functionality of the UPS.

Introduction

Alzheimer's disease (AD) is the most common form of dementia present in the aging population worldwide and the number of patients with AD is predicted to rise (1). According to the World Alzheimer Report 2018 (2), of the 50 million individuals in the world with dementia, two thirds were diagnosed with AD. While there have been numerous attempts to develop an effective drug for treating AD, only two types of drugs are currently available. One such type is cholinesterase inhibitors, such as donepezil, which function to prevent acetylcholinesterase from breaking down acetylcholine (3); therefore, signals are able to be transmitted between nerve cells. The other type of drug is an N-methyl-D-aspartic acid receptor antagonist (memantine), which acts to relieve the damage to nerve cells caused by excessive amounts of released glutamate (4). However, the currently available drugs are only able to provide symptomatic relief (5). Due to the high socioeconomic costs associated with patients with AD worldwide (6,7), the development of effective therapies to treat AD is of great significance.

Although the fundamental mechanisms underlying AD remain unknown, two classic pathological proteins, β-amyloid (Aβ) and tau, are reported to be involved (8). Aβ accumulates and forms amyloid plaques, which causes damage to the synapses (9). In addition to Aβ, hyperphosphorylated tau forms neurofibrillary tangles (NFT) inside neurons, and these tau aggregations block the neuronal transport system (10). The ubiquitin (Ub)-proteasome system (UPS) is a sophisticated mechanism for intracellular protein degradation and turnover (11). The ubiquitin (Ub)-proteasome system (UPS) is a sophisticated mechanism for intracellular protein degradation and turnover (11). Ub is a polypeptide that can label substrate proteins via the covalent attachment of multiple Ub molecules, such as Ub-activating enzyme E1 (UbE1) and Ub-conjugating enzyme E2 (UbE2). In addition, the 26S proteasome serves a major role in the degradation of Ub-conjugated proteins (12). Dysregulation of the UPS is of particular interest in the pathogenesis of AD, and emerging evidence has suggested that aberrant UPS activity may contribute to the disorder of Aβ and tau degradation (13,14).

Yuan-zhi-san (YZS) is a herbal drug in Traditional Chinese Medicine that has been clinically applied to treat dementia. Previous studies have revealed that YZS and its components are...
effective and safe in relieving some symptoms and improving cognitive impairment in patients with AD (15–17). Our previous study reported that YZS could improve learning and memory abilities in a D-galactose-induced aging mouse model, which was achieved, in part, by the attenuation of oxidative stress (18). A similar result was also reported by Jin et al (19). Moreover, our previous study using another scopolamine-induced mouse model of dysmnesia further validated the memory-improving ability of YZS (20). Qiang et al (21) observed that YZS relieved AD by regulating acetylcholine receptor activity and by binding to \( \text{A}\beta \). Furthermore, nearly 180 active ingredients of YZS demonstrating multi-component and multi-target characteristics have been screened, and a specific database of the active ingredients has been established (21). However, whether YZS has an impact on UPS-mediated tau degradation remains to be elucidated.

The present study aimed to investigate the effects of YZS on learning and memory abilities, as well as AD pathology, in an \( \text{A}\beta_1-40 \)-induced AD rat model. Moreover, it was determined whether YZS affected the phosphorylation of tau protein, and whether its potential therapeutic effects were achieved by modulating the UPS.

Materials and methods

Animals. Sprague-Dawley rats (n=40; equal number of males and females; weight, 200±20 g; age, 7 weeks) were obtained from Chengdu Dashuo Experimental Animal Co., Ltd. (animal license no. SYXK-2017-179). Animals were housed under controlled conditions of 22±2°C and 50±10% humidity, with a 12-h light/dark cycle and \( \text{ad libitum} \) access to standard rodent chow and water. The present study was approved by the Medical Ethics Committee of Chengdu University of Traditional Chinese Medicine (Chengdu, China; approval no. 2017-02).

Drugs. \( \text{A}\beta_{1-40} \) was purchased from Sigma-Aldrich; Merck KGaA (cat. no. A1075); donepezil was obtained from Shanxi Aark Pha. Ltd. (drug approval. no. H20030583; https://www.800pharm.com/shop/groupId_101169.html). YZS was composed of 12 g Radix polygala (Yuan Zhi), 12 g Rhizoma coctidis (Huang Lian), 15 g Sclerotium pori-acecos (Fu Ling), 9 g Radix ginseng (Ren Shen) and 18 g Acori Tatarinowii Rhizoma (Shi Chang Pu), and was prepared into a standardized granule formula by Sichuan Neo-Green Pharmaceutical Technology Development Co., Ltd.

AD animal model establishment and treatment. Sprague-Dawley rats were randomly divided into four groups: i) Sham group (n=10; treated with vehicle); ii) AD model group (n=10; treated with \( \text{A}\beta_{1-40} \) and vehicle); iii) AD model + donepezil group (n=10; treated with \( \text{A}\beta_{1-40} \) and donepezil); and iv) AD model + YZS group (n=10; treated with \( \text{A}\beta_{1-40} \) and YZS). The \( \text{A}\beta_1-40 \)-induced AD rat model was established as described previously (22-24). Following anesthetization with \( 0.45\% \) pentobarbital sodium, rats were sacrificed via transcardial perfusion with 0.9% saline (pH 7.4). Hippocampi were harvested, fixed in 4% paraformaldehyde solution for >24 h at 4°C, dehydrated in graded alcohol series (30, 50, 70, 95 and 100%) and embedded in paraffin. Samples were cut into 5-µm sections and then stained with H&E (hematoxylin at room temperature for 5 min; eosin at room temperature for 1 min) to examine the pathological alterations. Images were captured under a light microscope (IX71; Olympus Corporation) at a magnification of x400.

Hematoxylin & eosin (H&E) staining. Following anesthetization with 0.45% pentobarbital sodium, rats were sacrificed via transcardial perfusion with 0.9% saline (pH 7.4). Hippocampi were harvested, fixed in 4% paraformaldehyde solution for >24 h at 4°C, dehydrated in graded alcohol series (30, 50, 70, 95 and 100%) and embedded in paraffin. Samples were cut into 5-µm sections and then stained with H&E (hematoxylin at room temperature for 5 min; eosin at room temperature for 1 min) to examine the pathological alterations. Images were captured under a light microscope (IX71; Olympus Corporation) at a magnification of x400.

Golgi-Cox staining. After transcardial perfusion with 0.9% saline, hippocampi were collected and immersed in a vial containing Golgi-Cox solution (prepared solution from FD Rapid GolgiStain™ kit; cat. no. PK401; FD Neurotechnologies, Inc.). The vial was kept in the dark and the Golgi-Cox solution was replaced every alternate day for 2 weeks. Subsequently, the samples were transferred to a vial containing 30% sucrose solution and stored at 4°C in the dark for 6 days. The samples were cut into 100-µm sections and then rinsed with distilled water. Subsequently, the sections were treated with 22.5% ammonium hydroxide solution for 30 min and then with 5% thiosulphate solution for 30 min at room temperature. After rinsing with distilled water for 2 min, routine glass slides containing the sections were processed. Images were captured under a light microscope (Eclipse E100; Nikon Corporation) at magnification of x600. The density of the dendritic spines was measured using Image-pro plus 6.0 (Media Cybernetics, Inc.).

Transmission electron microscopy. A small portion of the hippocampus was fixed in 2.5% glutaraldehyde in cacodylate buffer (pH 7.4) at 4°C for 4 h and were post-fixed in 2% osmium tetroxide at 4°C for 1 h in the same buffer. Subsequently, the tissues were routinely dehydrated in acetone, infiltrated and embedded in epoxy resin-filled capsules. Finally, 70-nm ultrathin sections were prepared with an LKB ultramicrotome.
and counterstained with 2% aqueous uranyl acetate for 10 min and 0.8% lead citrate for 2 min at room temperature. The ultrastructure of nerve cells was observed and imaged under a transmission electron microscope (TEM; magnification, x2,500 and x6,000; H-7650; Hitachi Ltd.).

**Immunohistochemistry.** Brain tissues were fixed in 4% paraformaldehyde at 4°C for 24 h, dehydrated and embedded in paraffin. Paraaffin-embedded specimens were sliced into 3-µm sections, dewaxed and rehydrated. After routine peroxidase blocking for 10 min and blocking with 5% BSA (cat. no. G5001; Wuhan Servicebio Technology Co., Ltd.) for 30 min at room temperature, the sections were incubated with antibodies against Tau5 (1:100; cat. no. MAB361; EMD Millipore), phosphorylated (p)-Tau (Ser199; 1:100; cat. no. 44-734G; Invitrogen; Thermo Fisher Scientific, Inc.), p-Tau (Thr231; 1:100; cat. no. 11110; Signalway Antibody LLC) and p-Tau (Ser396; 1:100; cat. no. 11102; Signalway Antibody LLC) overnight at 4°C. The sections were then exposed to horse-radish peroxidase (HRP)/Fab polymer-conjugated secondary antibodies (solution from the kit; cat. no. PV-6000-D; OriGene Technologies, Inc.) at room temperature for 30 min, followed by staining with 3,3'-diaminobenzidine solution at room temperature for 5 min and counterstaining with hematoxylin at room temperature for 20 sec. To evaluate the protein expression levels, three visual fields were randomly selected from each slice under a light microscope (magnification, x400). Images were acquired and analyzed using Image Pro Plus 6.0 software (Media Cybernetics, Inc.). Quantification of expression levels was determined using mean integrated optical density (IOD).

**Western blotting.** Hippocampal sections were homogenized in pre-cooled RIPA buffer (cat. no. G2002; Wuhan Servicebio Technology Co., Ltd.) containing a protease inhibitor cocktail, and homogenates were then incubated on ice for 10 min and centrifuged at 16,128 x g at 4°C for 15 min. The protein concentration was determined using a commercial BCA kit (cat. no. P0010S; Beyotime Institute of Biotechnology). Proteins (30 µg) were separated by SDS-PAGE on 8-10% gels and transferred onto PVDF membranes. The membranes were blocked with 5% skimmed milk in Tris-buffered saline containing 0.05% Tween-20 (TBST) at room temperature for 1 h and incubated at 4°C overnight with primary antibodies against UbE1a/b (1:1,000; cat. no. 4891; Cell Signaling Technology, Inc.), UbE2a (1:500; cat. no. 11080-1-AP; ProteinTech Group, Inc.), carboxyl terminus of Hsc70-interacting protein (CHIP; 1:1,000; cat. no. 2080; Cell Signaling Technology, Inc.), Ub C-236 terminal hydrolase L1 (UCH-L1; 1:1,000; cat. no. 14730-1-AP; ProteinTech Group, Inc.), 26S proteasome (1:500; cat. no. sc-65755; Santa Cruz Biotechnology, Inc.) and β-actin (1:4,000; cat. no. 200068-SF10; Chengdu Zen BioScience Co., Ltd.). After washing three times with TBST, the membranes were incubated at room temperature for 1 h with HRP-conjugated secondary antibodies (1:3,000; cat. nos. GB23301 and GB23303; Wuhan Servicebio Technology Co., Ltd.). An enhanced chemiluminescence kit (cat. no. NEL103E001EA; PerkinElmer, Inc.) was used to detect the bands using a Molecular Imager PharosFX Plus system (Bio-Rad Laboratories, Inc.), and the bands were analyzed and semi-quantified using Quantity One software system (ver. no. 4.6.9; Bio-Rad Laboratories, Inc.).

**Statistical analysis.** Statistical analyses were performed using SPSS 17.0 software (SPSS, Inc.). Differences between groups were evaluated using one-way ANOVA followed by Tukey's or Dunnett's T3 post hoc tests. Data are presented as the mean ± SD from three independent experiments. P<0.05 was considered to indicate a statistically significant difference.

**Results**

**YZS rescues the memory deficit of AD rats.** The memory and learning performances of YZS-treated AD rats were examined using a Morris water maze test. As expected, the mean escape latency of all rats declined during the training period. On day 4, AD rats demonstrated a significantly longer escape latency in the orientation navigation experiment compared with that of sham-operated rats (P<0.01). It was demonstrated that, similar to the effects of donepezil administration, YZS administration shortened the escape latency (P<0.05; Fig. 1B). In the probe test, YZS-treated AD rats had greater crossing times (P<0.01; Fig. 1C), increased time in the target quadrant (P<0.01; Fig. 1D) and lengthier swimming routes (P<0.01; Fig. 1E) compared with those of AD rats. These results indicated the rescuing effect of YZS on the memory and learning abilities of AD rats.

**YZS ameliorates AD histopathology and ultrastructural abnormalities.** H&E staining indicated that the number of neurons in the CA1 region was markedly lower in AD rats compared with in the sham-operated rats (Fig. 2A). Both donepezil- and YZS-treated AD rats had notably increased numbers of neurons. These results suggested that YZS could protect against neuronal loss in AD rats.

The ultrastructural examination of nerve cells in the hippocampus using a TEM demonstrated a visible difference between AD and sham-operated rats. In nerve cells from AD rats, the nuclei were swollen and shaped like grapes, along with chromatin condensation and nuclear membrane invagination. The presence of swollen mitochondria with broken cristae and an expanded endoplasmic reticulum was also observed. However, both donepezil and YZS intervention appeared to reverse the aberrant morphological ultrastructure in terms of nuclei, mitochondria and endoplasmic reticulum (Fig. 2B). Taken together, these findings indicated that YZS could effectively restore the number of neurons and reduce ultrastructural abnormalities in the brain of AD rats.

**YZS enhances the density of dendritic spines in AD rats.** To further examine the neuroprotective effect of YZS against Aβ-induced AD, the density of dendritic spines was measured using Golgi-Cox staining (Fig. 3A). AD rats had a significantly lower density of dendritic spines compared with sham-operated rats (P<0.01; Fig. 3B). Moreover, YZS treatment could protect against the loss of dendritic spines in the brain of AD rats, which was reflected by an increased density of dendritic spines in AD rats treated with YZS or donepezil (P<0.01; Fig. 3B). Notably, the protective capability of YZS...
YZS inhibits the hyperphosphorylation of tau protein in AD rats. Tau is a microtubule-associated protein that, in a hyperphosphorylated state, is considered to self-assemble into a paired helical filament, and ultimately contribute to the NFT pathology of AD (10). The results of the present study detected no significant differences in the expression of total tau5 protein among all rats (P>0.05; Fig. 4A and B). Conversely, YZS administration significantly inhibited the hyperphosphorylation of tau protein at Ser199 and Thr231 sites (P<0.01; Fig. 4A, C and E). Although p-Tau Ser396 was identified to be hyperphosphorylated in AD rats, the hyperphosphorylation level of p-Tau Ser396 was barely reduced by YZS treatment (P>0.05 Fig. 4A and D). These results indicated that YZS could suppress hyperphosphorylation of tau protein (Ser199 and Thr231), thereby decreasing its self-assembly into paired helical filaments and reducing the NFT pathology in AD rats.

YZS modulates the expression levels of UPS-related proteins in AD rats. The UPS is essential for degrading misfolded and damaged intracellular proteins, including tau degradation, and it has been reported that an impaired UPS is involved in AD pathogenesis (26). Thus, it was investigated whether YZS could restore functionality of the UPS by impacting several vital enzymes involved in the complex enzymatic cascade of UPS, including UbE1a/b, UbE2a, CHIP, UCH-L1 and 26S proteasome. Western blot analysis identified that the protein expression levels of UbE1a/b, UbE2a, CHIP, UCH-L1 and 26S proteasome were all significantly downregulated in the AD model rats (P<0.01 or P<0.05; Fig. 5A-E), which suggested an impaired enzymatic cascade of the UPS. When compared with the AD model rats, these enzymes were upregulated in the brains of AD rats co-treated with YZS or donepezil (P<0.01; Fig. 5A-E). These findings indicated that YZS could, at least in part, effectively upregulate the protein expression levels of UbE1a/b, UbE2a, CHIP, UCH-L1 and 26S proteasome, which may facilitate restoration of the UPS to remove tau accumulation.

Discussion

AD is mainly characterized by a progressive loss of memory and the development of cognitive deficits, leading to profound dementia. It has been suggested that the two pathological hallmarks of AD include extracellular Aβ plaques and intracellular tau tangles (8). Due to the huge socioeconomic burden caused by AD globally (6,7), discovering potential effective therapies to treat AD is of great importance. Several studies
have revealed the neuroprotective effects of YZS, with its multi-component and multi-target characteristics (18-21).

To verify the present hypothesis that YZS may enhance learning and memory abilities partly by restoring UPS-mediated tau degradation, an Aβ-induced AD rat model treated with YZS was established. The present results demonstrated that treatment with YZS, similar to donepezil, improved learning and memory, and restored the number of neurons and reversed ultrastructural abnormalities. Furthermore, YZS could protect against the loss of dendritic spines in the brains of AD rats. These findings suggested that YZS may serve as an effective herbal formula that brings relief to AD rats.

In the past two decades, a positive association has been identified between pathological tau aggregation and the progression of AD (27). Ultrastructurally, when tau, a microtubule-associated protein, is in an abnormally hyperphosphorylated state it is consequently incapable of binding to microtubules and thus self-assembles into paired helical

Figure 2. Effects of YZS on the morphology and number of neurons in Alzheimer's disease model rats. (A) Representative images of hippocampal neurons from the CA1 region using hematoxylin and eosin (H&E) staining (magnification, x400). (B) Representative images indicating the ultrastructure of nerve cells using transmission electron microscopy (magnification, x2,500 and x6,000). Orange arrows indicate nuclear membrane; blue arrows indicate endoplasmic reticulum; green arrows indicate mitochondrion. YZS, Yuan-zhi-san.

Figure 3. Effects of YZS on the density of dendritic spines in Alzheimer's disease model rats. (A) Representative images of dendritic spines in the brain tissues using Golgi-Cox staining (magnification, x600). (B) Analysis of density of dendritic spines in each group. Data are presented as the mean ± SD (rats n=6). ##P<0.01 vs. Sham group; *P<0.05; **P<0.01 vs. Model group. YZS, Yuan-zhi-san.
filaments. Studies have reported that paired helical filaments serve as the major fibrous component of NFTs found in cell bodies and apical dendrites (10). Abundant NFTs distribute in the nerve cells that undergo degeneration and their degree of abundance has been shown to be closely associated with the severity of AD (28). In the current study, hyperphosphorylated tau protein at Ser199, Ser396 and Thr231 sites was observed in AD model rats. Tau hyperphosphorylation at Ser199 and Thr231 was significantly decreased following YZS treatment, which may contribute to the remission of AD pathology. However, it was revealed that YZS treatment exhibited little effect on tau hyperphosphorylation at Ser396; a possible reason for this is that p-Tau Ser396 may not be a potential target of YZS.

The UPS is essential for degrading misfolded and damaged intracellular proteins, including tau degradation. Therefore, the present study investigated whether YZS was capable of regulating the expression of UPS-related molecules, which are critical for functionality of the UPS and may contribute to tau degradation. Ub-activating enzymes
(UbE1) form a thioester bond with Ub via an ATP-dependent mechanism. Subsequently, Ub is shifted to Ub-conjugating enzymes (UbE2), which function as scaffold proteins that favor the interaction between Ub ligase (E3) and the target substrate protein (11), allowing the ligase to transfer the Ub from E2 to the substrate protein (11). Polyubiquitinated proteins are subsequently recognized and degraded by the 26S proteasome into small peptides (12). It has been reported that the 26S proteasome can degrade phosphorylated and non-phosphorylated tau proteins (29). In the UPS, CHIP, an E3 ligase, facilitates UPS-mediated tau degradation, and the activity of CHIP has been reported to be impaired in the human AD brain (30,31), suggesting that CHIP inhibition may lead to tau accumulation and exacerbation of AD pathology.

Moreover, UCH-L1 is a protease belonging to the deubiquitinating enzyme family, which removes Ub from Ub chains or the substrate (32). It has been established that inhibition of UCH-L1 activity may decrease the microtubule-binding ability and increase the phosphorylation of tau protein (33).

The present study demonstrated that the expression levels of UbE1a/b, UbE2a, CHIP, UCH-L1 and 26S proteasome were significantly decreased in the brains of AD rats, which indicated an impaired enzymatic cascade of the UPS. Moreover, co-administration with YZS partly increased the expression levels of these enzymes, suggesting that YZS may be beneficial in restoring functionality of the UPS, so as to regain the ability to degrade ubiquitinated and hyperphosphorylated tau protein. Future studies should focus on in vitro experiments to further understand the molecular mechanisms underlying the regulatory effect of YZS on the UPS.

In conclusion, the present study demonstrated that YZS may improve the learning and memory abilities, and reduce the severity of AD pathology in an Aβ-induced AD rat model. Furthermore, it was identified that YZS could suppress the
hyperphosphorylation of tau protein, which may be partially associated with its beneficial role in restoring functionality of the UPS.

Acknowledgements

Not applicable.

Funding

This work was supported by the National Natural Science Foundation of China (grant no. 81704024), the Sichuan Science and Technology Program (grant no. 2021YJ0435), the ‘Xing-lin Scholars’ Project of Chengdu University of TCM (grant nos. QNXZ2019014 and QNXZ2019017) and the ‘Hundred Talents Program’ of the Hospital of Chengdu University of Traditional Chinese Medicine (grant nos. 20-Y01 and 20-Q05).

Availability of data and materials

The datasets used and/or analyzed during the current study are available from the corresponding author on reasonable request.

Authors’ contributions

BL, JHZ and YZ designed the study. JG and PJX carried out the experiments. JRY and YG interpreted the results of the experiments. YWH and DYG organized the database and conducted the statistical analysis. BL and PJX prepared the manuscript. YZ and JHZ confirmed the authenticity of all the raw data. All authors have read and approved the final version of the manuscript.

Ethics approval and consent to participate

The present study was approved by the Medical Ethics Committee of Chengdu University of Traditional Chinese Medicine (approval no. 2017-02).

Patient consent for publication

Not applicable.

Competing interests

The authors declare that they have no competing interests.

References

1. Reitz C, Brayne C and Mayeux R: Epidemiology of Alzheimer disease. Nat Rev Neurol 7: 137-152, 2011.
2. Zhang HN, Wang MR, Chen XL, Xu YJ, Li J, Wang HL and Du J: Research on the content construction of dementia management in community based on Delphi method. Chin Gen Pract 23: 2072-2079, 2020.
3. Haake A, Nguyen K, Friedman L, Chakkaramambil B and Grossberg GT: An update on the utility and safety of cholinesterase inhibitors for the treatment of Alzheimer’s disease. Expert Opin Drug Saf Feb 19: 147-157, 2020.
4. Tzova NV: Memantine: From the original brand to generics. Zh Nevrol Psikhiatr Im S S Korsakova 117: 136-143, 2017 (In Russian).
5. Patterson C: World Alzheimer report 2018-The state of the art of dementia research: New frontiers. Alzheimer’s Disease International (ADI): 1-48, 2018.
6. El-Hayek YH, Wiley RE, Khoury CP, Daya RP, Ballard C, Evans AR, Karran M, Molinuevo JL, Norton M and Atri A: Tip of the iceberg: Assessing the global socioeconomic costs of Alzheimer's disease and related dementias and strategic implications for stakeholders. J Alzheimers Dis 70: 323-341, 2019.
7. Jia J, Wei C, Chen S, Li F, Tang Y, Qin W, Zhao L, Jin H, Xu H, Wang F, et al: The cost of Alzheimer's disease in China and re-estimation of costs worldwide. Alzheimers Dement 14: 483-491, 2018.
8. Roberson ED and Mucke L: 100 years and counting: Prospects for defeating Alzheimer's disease. Science 314: 781-784, 2006.
9. Zhang H and Zheng Y: β amyloid hypothesis in Alzheimer's disease: Pathogenesis, prevention, and management. Zhongguo Yi Xue Ke Xue Yuan Xue Bao 41: 702-708, 2019 (In Chinese).
10. Goedert M: Tau protein and the neurofibrillary pathology of Alzheimer's disease. Trends Neurosci 16: 460-465, 1993.
11. Tramutola A, Di Domenico F, Barone E, Perluigi M and Butterfield DA: It is all about (U)biqitin: Role of altered ubiquitin-proteasome system and UCHL1 in Alzheimer disease. Oxid Med Cell Longev 2016: 2756608, 2016.
12. Al Mamun AA, Uddin MS, Kabir MT, Khanam S, Sarwar MS, Mathew B, Rauf A, Ahmed M and Ashraf GM: Exploring the promise of targeting ubiquitin-proteasome system to combat Alzheimer’s disease. Neurotox Res 38: 8-17, 2020.
13. Lee MJ, Lee JH and Rubinsztein DC: Tau degradation: The ubiquitin-proteasome system versus the autophagy-lysosome system. Prog Neurobiol 105: 49-59, 2013.
14. Sulistio YA and Heese K: The ubiquitin-proteasome system and molecular chaperone deregulation in Alzheimer's disease. Mol Neurobiol 53: 905-931, 2016.
15. Liu G, He WB, Zhao QZ, Chu SF and Chen NH: Screening of core herbal combinations in anti-Alzheimer prescriptions by using Traditional Chinese Medicine Inheritance System. Chin J Exp Traditional Med Formulae 22: 223-228, 2016.
16. Zheng MY: Treatment of Alzheimer's dementia in Taiyin people with shiquipu Yuanzhi powder. J Med Pharm Chin Minorities 16: 16-17, 2010.
17. Sun ZL, Wang MJ, Wang LJ, Wang F and Li B: Theoretical discussion on treatment of senile dementia by supplementing Qi, inducing resuscitation and clearing away heart fire. J Basic Chin Med 23: 1374-1375+1401, 2017.
18. Guo J, Li B, Wang ZC, Wu YX, Yang Q and Chen X: Effects of yunzhi powder on learning and memory ability and oxidative stress level of D-galactose induced aging mice. Chin Arch Traditional Chin Med 37: 2144-2147+2314, 2019.
19. Jin YS, Li ML, Jin X, Zhao M, Lu HJ and Xu QS: Effects of Shichangpuyanzenhsian on learning and memory abilities in mice model with Alzheimer's disease. J Med Sci Yanbian Uni 37: 108-111, 2014.
20. Li B, Sun ZL, Chen GR, Zheng YQ, He XJ, Li GM, Yang R, Zou SZ and Chen LW: Effects of Yuanzhi san on ethology and cerebral acetylcholinesterase activity of memory disorder mouse model induced by scopolamine. J Guangzhou Uni Traditional Chin Med 23: 743-756, 2017.
21. Qiang WJ, Chen Y, He FY, Xiao MF, Cai WY, Dai YF, Yang Q, Li YJ, Weng XG, Li Q, et al: Molecular biological mechanisms of Yuan Zhi powder in the treatment of Alzheimer's disease: An analysis based on network pharmacology. Digital Chin Med 1: 90-101, 2018.
22. Lin J, Gao S, Wang T, Shen Y, Yang W, Li Y and Hu H: Ginsenoside Rb1 improves learning and memory ability through its anti-inflammatory effect in ApoE-/- induced Alzheimer's disease of rats. Am J Transl Res 11: 2955-2968, 2019.
23. Zhao J, Lu S, Yu H, Duan S and Zhao F: Baicalin and ginsenoside Rb1 promote the proliferation and differentiation of neural stem cells in Alzheimer's disease model rats. Brain Res 1678: 187-194, 2018.
26. Gentier RJ and van Leeuwen FW: Misframed ubiquitin and impaired protein quality control: An early event in Alzheimer's disease. Front Mol Neurosci 8: 47, 2015.

27. Gao Y, Tan L, Yu JT and Tan L: Tau in Alzheimer's disease: Mechanisms and therapeutic strategies. Curr Alzheimer Res 15: 283-300, 2018.

28. Lacosta AM, Insua D, Badi H, Pesini P and Sarasa M: Neurofibrillary tangles of Aβx-40 in Alzheimer's disease brains. J Alzheimers Dis 58: 661-667, 2017.

29. Zhang JY, Liu SJ, Li HL and Wang JZ: Microtubule-associated protein tau is a substrate of ATP/Mg(2+)-dependent proteasome protease system. J Neural Transm (Vienna) 112: 547-555, 2005.

30. Keck S, Nitsch R, Grune T and Ullrich O: Proteasome inhibition by paired helical filament-tau in brains of patients with Alzheimer's disease. J Neurochem 85: 115-122, 2003.

31. Keller JN, Hanni KB and Markesbery WR: Impaired proteosome function in Alzheimer's disease. J Neurochem 75: 436-439, 2000.

32. Nijman SM, Luna-Vargas MP, Velds A, Brummelkamp TR, Dirac AM, Sixma TK and Bernards R: A genomic and functional inventory of deubiquitinating enzymes. Cell 123: 773-786, 2005.

33. Xie M, Han Y, Yu QT, Wang X, Wang SH and Liao XM: UCH-L1 inhibition decreases the microtubule-binding function of tau protein. J Alzheimers Dis 49: 353-363, 2016.

This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0) License.